Viridian Therapeutics, Inc. (VRDN)

NCM – Real Time Price. Currency in USD

16.86

-0.34 (-1.98%)

At close: May 12, 2026, 4:00 PM EDT

16.80

-0.06 (-0.36%)

After-hours: May 12, 2026, 7:39 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Viridian Therapeutics, Inc. (VRDN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market

Viridian eye disease drug benefits chronic patients in late-stage trial

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Videos

No Data

Press releases

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Search stocks

Viridian Therapeutics, Inc. (VRDN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease Transcript

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market

Viridian eye disease drug benefits chronic patients in late-stage trial

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease

Videos

No Data

Press releases

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease